▲ +40.46% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Ortho Clinical Diagnostics in the last 3 months. The average price target is $24.30, with a high forecast of $27.00 and a low forecast of $20.00. The average price target represents a 40.46% upside from the last price of $17.30.
The current consensus among 11 investment analysts is to buy stock in Ortho Clinical Diagnostics.
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business in the United States. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a broad spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides ortho-care services. Its products are used in hospitals and laboratories; and physician offices, clinics, blood banks, donor centers, and other specialty settings. The company was founded in 1939 and is headquartered in Raritan, New Jersey.